News from us and our partners

Tags

Topics

0 results

News
29 September, 2022
AFYREN inaugurates its first factory, AFYREN NEOXY, a first-of-its-kind biorefinery
News
26 September, 2022
TISSIUM appoints Sara Toyloy as independent Board member
News
21 September, 2022
NodThera announces positive Phase 1 study readouts for the NLRP3 inflammasome inhibitors NT-0796 and NT-0249
News
21 September, 2022
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China
News
13 September, 2022
Antoine Papiernik and Sylvain Gariel urge France to invest in vaccines
News
9 September, 2022
May Health solidifies veteran executive team with appointment of women’s health care leader Anne Morrissey as CEO
News
8 September, 2022
AAVantgarde Bio appoints Dr. Natalia Misciattelli as Chief Executive Officer
News
6 September, 2022
Synthace appoints Dr. Donald Deieso as new Board Chair
News
6 September, 2022
Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study
News
2 September, 2022
Abivax announces successful oversubscribed €49.2 million crossover financing with top-tier U.S. and European biotech investors
News
30 August, 2022
Sofinnova's Henrijette Richter talks to BioCentury about creating support networks for first-time CEOs
News
22 August, 2022
Pi-Cardia successfully performs mitral valve splitting with ShortCut(TM)
News
10 August, 2022
Nephris welcomes discovery of novel pathogenic factor in diabetic kidney disease
News
8 August, 2022
CinCor Pharma announces positive topline data for Phase 2 BrigHtn trial evaluating baxdrostat, its selective aldosterone synthase inhibitor, in treatment-resistant hypertension
News
4 August, 2022
F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim
News
4 August, 2022
Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder

AFYREN inaugurates its first factory, AFYREN NEOXY, a first-of-its-kind biorefinery

TISSIUM appoints Sara Toyloy as independent Board member

NodThera announces positive Phase 1 study readouts for the NLRP3 inflammasome inhibitors NT-0796 and NT-0249

Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China

Antoine Papiernik and Sylvain Gariel urge France to invest in vaccines

May Health solidifies veteran executive team with appointment of women’s health care leader Anne Morrissey as CEO

AAVantgarde Bio appoints Dr. Natalia Misciattelli as Chief Executive Officer

Synthace appoints Dr. Donald Deieso as new Board Chair

Noema Pharma announces completion of enrollment in the Trigeminal Neuralgia Electronic Diary (TNED) validation study

Abivax announces successful oversubscribed €49.2 million crossover financing with top-tier U.S. and European biotech investors

Sofinnova's Henrijette Richter talks to BioCentury about creating support networks for first-time CEOs

Pi-Cardia successfully performs mitral valve splitting with ShortCut(TM)

Nephris welcomes discovery of novel pathogenic factor in diabetic kidney disease

CinCor Pharma announces positive topline data for Phase 2 BrigHtn trial evaluating baxdrostat, its selective aldosterone synthase inhibitor, in treatment-resistant hypertension

F2G announces $70 million financing to advance development and commercialization of new antifungal agent olorofim

Noema Pharma announces recruitment of first patient in Orpheus Phase 2b Study of PDE10A inhibitor gemlapodect in adults with childhood onset fluency disorder